HER2 Support Group Forums - View Single Post - now it's radiation recall dermatitis from herceptin!

Lani · 04-02-2013, 09:34 PM

Breast Cancer. 2013 Mar 31. [Epub ahead of print]
Radiation recall dermatitis induced by trastuzumab.
Moon D, Koo JS, Suh CO, Yoon CY, Bae J, Lee S.
Source
Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea.
Abstract
We report a case of radiation recall dermatitis caused by trastuzumab. A 55-year-old woman with metastatic breast cancer received palliative first-line trastuzumab/paclitaxel and a salvage partial mastectomy with lymph node dissection was subsequently performed. In spite of the palliative setting, the pathology report indicated that no residual carcinoma was present, and then she underwent locoregional radiotherapy to ensure a definitive response. After radiotherapy, she has maintained trastuzumab monotherapy. Nine days after the fifth cycle of trastuzumab monotherapy, dermatitis in previously irradiated skin developed, with fever. Radiation recall dermatitis triggered by trastuzumab is extremely rare. A high fever developed abruptly with a skin rash. This may be the first case of this sort to be reported.
PMID: 23543400 [PubMed - as supplied by publisher]

04-02-2013, 09:34 PM	#1
Lani Senior Member Join Date: Mar 2006 Posts: 4,778	now it's radiation recall dermatitis from herceptin! Breast Cancer. 2013 Mar 31. [Epub ahead of print] Radiation recall dermatitis induced by trastuzumab. Moon D, Koo JS, Suh CO, Yoon CY, Bae J, Lee S. Source Department of Internal Medicine, Yonsei University College of Medicine, 50 Yonsei-ro, Seodaemun-gu, Seoul, 120-752, Republic of Korea. Abstract We report a case of radiation recall dermatitis caused by trastuzumab. A 55-year-old woman with metastatic breast cancer received palliative first-line trastuzumab/paclitaxel and a salvage partial mastectomy with lymph node dissection was subsequently performed. In spite of the palliative setting, the pathology report indicated that no residual carcinoma was present, and then she underwent locoregional radiotherapy to ensure a definitive response. After radiotherapy, she has maintained trastuzumab monotherapy. Nine days after the fifth cycle of trastuzumab monotherapy, dermatitis in previously irradiated skin developed, with fever. Radiation recall dermatitis triggered by trastuzumab is extremely rare. A high fever developed abruptly with a skin rash. This may be the first case of this sort to be reported. PMID: 23543400 [PubMed - as supplied by publisher]